Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients
NCT ID: NCT05525741
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
59 participants
INTERVENTIONAL
2022-10-19
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitiligo Group
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Non segmental vitiligo
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.
The Investigator:
* Inform the subject of the goals, constraints and risks of the study and obtain written consent.
* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Volunteers Group
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Health Volunteers
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.
The Investigator:
* Inform the subject of the goals, constraints and risks of the study and obtain written consent.
* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Health Volunteers
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.
The Investigator:
* Inform the subject of the goals, constraints and risks of the study and obtain written consent.
* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Non segmental vitiligo
The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.
The Investigator:
* Inform the subject of the goals, constraints and risks of the study and obtain written consent.
* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.
If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* atopic dermatitis, psoriais, alopecia areata,
* 1st degree relative of vitiligo patients.
Exclusion Criteria
* personnal history of other autoimmune disorders,
* oral use of antioxidant,
* pregant women
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
passeron thierry, PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Nice, Service de Dermatologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-maritimes, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-PP-10
Identifier Type: -
Identifier Source: org_study_id